REGENXBIO Inc.
RGNX
$7.77
$0.010.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -31.19% | -3.93% | -33.75% | 109.61% | 18.61% |
| Total Depreciation and Amortization | -3.83% | -1.89% | -3.60% | -5.38% | -7.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 229.44% | 38.23% | 34.89% | -39.43% | -54.71% |
| Change in Net Operating Assets | -115.43% | -270.88% | 286.77% | 301.20% | 26.39% |
| Cash from Operations | -65.35% | -38.01% | -8.45% | 160.64% | 22.41% |
| Capital Expenditure | 52.92% | -50.61% | 17.51% | -83.84% | 4.17% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.99% | -15.43% | -68,083.01% | 233.09% | 17.81% |
| Cash from Investing | -6.79% | -15.86% | -52,301.49% | 239.40% | 18.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 136.84% | -17.02% | -- | -99.66% | -81.82% |
| Repurchase of Common Stock | -- | -- | 100.00% | 43.96% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -24.38% | 34.46% | 1,582.25% | 49.02% | 36.09% |
| Cash from Financing | -23.82% | 34.76% | 1,574.13% | -104.80% | 35.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,777.23% | -1,708.01% | 8.45% | -7.49% | 104.85% |